Market evolution: Pacemakers (CN 902150) — 2015–2025

Introduction

This report analyses the trade dynamics of the European Union concerning pacemakers for stimulating heart muscles (Customs code 902150) over the 2015–2025 period. Based on the provided trade data, the EU demonstrates a strengthening position as a net exporter in this high-value medical device sector. Key trends include a significant increase in export value and volume, a geographic shift in import sources towards Asia, and a consistent decline in average unit prices, pointing towards market maturation and increased global competition. The analysis draws from the general trade overview and related modules.

I. The EU Strengthens its Role as a Major Net Exporter

The EU's trade balance for pacemakers has widened considerably, transitioning from a positive position to a substantial and growing surplus over the decade. This underscores the bloc's competitive strength in manufacturing and exporting these critical medical devices.

1. Robust Export Growth Outpaces Import Increases

From 2015 to 2025, the value of EU pacemaker exports grew by 49.0%, reaching €2.37 billion. In contrast, imports increased by 23.8% to €1.57 billion. This divergence caused the trade surplus to more than double, rising from €323 million to €802 million (+148.1%), as detailed in the trade balance section.

2. Significant Volume Expansion, Particularly in Exports

The growth in value is supported by a massive expansion in trade volumes. Export quantities (by mass) surged by 121.7%, while import quantities rose by 31.9%. The even larger increase in export supplementary unit counts (the number of items exported, +119.0%) suggests that the EU not only exported more but also likely shifted its export mix towards higher volumes of products, possibly including more models or complete units.

3. Internal EU Trade Dynamics Reflect Specialization

Within the EU, trade specialization is pronounced. In 2025, Ireland and the Netherlands were the top exporters, accounting for a combined €1.56 billion. Conversely, several large member states like Germany and France saw their import volumes from non-EU countries collapse by over 97% between the first and last period, indicating a potential consolidation of import hubs within the EU (e.g., in Belgium and the Netherlands) or a shift towards sourcing from intra-EU production. This is highlighted in the data on top reporting EU member states.

II. Geographic Reorientation of Import Sources Towards Asia

The origin of pacemakers imported into the EU has shifted significantly. While Switzerland remains the dominant supplier, its share has been diluted by the rapid growth of imports from Southeast Asia and other regions.

1. Switzerland as the Uncontested but Stable Partner

Switzerland is by far the EU's largest import source, with the value of its exports to the EU growing modestly by 4.4% to €899 million. However, its share of total EU imports has decreased as other suppliers have grown faster. The top partners data shows its concentration (HHI) decreased by 22.8%, indicating a diversification of the EU's import base.

2. The Rise of Asian Suppliers: Singapore and Malaysia

A defining trend is the dramatic growth of imports from Singapore and Malaysia. Imports from Singapore grew by 52.4% to €171 million, while those from Malaysia exploded by 199.4% to €254 million. This points to these countries becoming increasingly important manufacturing or distribution hubs for global medtech firms serving the EU market.

3. Diversification with Other Key Partners

Other notable partners include the United States (+29.9%) and a significant, albeit smaller, emerging trade link with Uruguay (+517.4%). The UK, a former major partner within the EU, has seen its direct exports to the EU decline by 30.8% since 2015, likely reflecting post-Brexit trade adjustments.

III. Declining Unit Prices Indicate Competitive Pressure and Market Maturation

A consistent theme across both exports and imports is the decline in average unit prices (value per tonne and per piece), suggesting competitive pressures and potential technological commoditization.

1. Substantial Decline in Export Unit Prices

The average price per exported unit (EUR/piece) fell by 32.0% over the period, from €2,929 to €1,993. This is a more pronounced drop than the 29.7% decline in price per tonne, indicating that the products exported may have become lighter or that lower-priced models are being exported in greater volume.

2. Modest Price Decline in Imports

Import prices also fell, though less dramatically. The average price per imported unit decreased by 6.2% to €4,390. Notably, the price per tonne for imports fell by only 6.2%, while the price per piece fell more sharply. This suggests that the unit (piece) of imported pacemakers may have become lighter on average, or the mix shifted towards lower-cost devices.

3. Price Volatility Highlights Supply Chain Sensitivity

The volatility analysis reveals that some trade flows are highly sensitive to price shocks. For instance, a major price shock was detected in exports to Switzerland in 2017 (price shift of +256.5%). Similarly, exports to the UK showed extreme price volatility (coefficient of variation of 1.89), which could reflect one-off contracts or significant changes in product mix.

Conclusion

Over the 2015–2025 period, the EU pacemaker market has evolved into a robust net-export industry characterized by strong volume growth, strategic diversification of import sources, and intense price competition. The EU's trade surplus has more than doubled, powered by a major expansion in export volumes, particularly to the United States and the United Kingdom. On the import side, a clear geographic shift towards Singapore and Malaysia is evident, reducing reliance on traditional partners and slightly lowering supply chain concentration, as measured by the Herfindahl-Hirschman Index (HHI). Concurrently, declining unit prices across both exports and imports point towards a mature, highly competitive global market where cost efficiencies and possibly lower average selling prices for devices are becoming the norm. The EU's position as a major exporter, coupled with its highly specialized production concentrated in a few member states, underscores its strategic importance in the global medtech supply chain for cardiac devices.